Human cathelicidin-derived LL-37 is a 37-residue cationic, amphipathic α-helical peptide. It is an active component of mammalian innate immunity. LL-37 has several biological functions including a broad spectrum of antimicrobial activities and LPS-neutralizing activity. In order to determine the high-resolution three-dimensional structure of LL-37 using NMR spectroscopy, it is important to obtain the peptide with isotopic labels such as 15 N, 13 C and/or 2 H. Since it is less expensive to obtain such a peptide biologically, in this study, we report for the first time a method to express in E. coli and purify LL-37 using Glutathione S-transferase (GST) fusion system. LL-37 gene was inserted into vector pGEX-4T3 and expressed as a GST-LL-37 fusion protein in BL21(DE3) strain. The recombinant GST-LL-37 protein was purified with a yield of 8 mg/l by affinity chromatography and analyzed its biochemical and spectroscopic properties. Factor Xa was used to cleave a 4.5-kDa LL-37 from the GST-LL-37 fusion protein and the peptide was purified using a reverse-phase HPLC on a Vydac C 18 column with a final yield of 0.3 mg/l. The protein purified using reverse-phase HPLC was confirmed to be LL-37 by the analyses of Western blot and MALDI-TOF-Mass spectrometry. E. coli cells harboring the expression vector pGEX-4T3-LL-37 were grown in the presence of the 15 N-labeled M9 minimal medium and culture conditions were optimized to obtain uniform 15 N enrichment in the constitutively expressed LL-37 peptide. These results suggest that our production method will be useful in obtaining a large quantity of recombinant LL-37 peptide for NMR studies.
Introduction
Increasing resistance of virtually all microbes toward common antibiotics that have provided safety for the last half a century is a major concern presently in the health science. Natural antimicrobial peptides probably represent one of the very first evolved forms of chemical defense of living eukaryotic cells against invasion by other living organisms [1, 2] . Antimicrobial peptides have survived in this role over evolutionary time scales, likely due to the fact that they are less susceptible to the development of bacterial resistance because they disrupt the membrane of bacteria through non-specific peptide-lipid interactions. These peptides show a broad spectrum of antimicrobial activities against Gram-negative and Gram-positive bacteria, and fungi. LL-37 is an antimicrobial peptide with 37 amino acid residues found in human and has been shown to play a vital role in innate immunity. It is a 4.5-kDa cationic, amphipathic αhelical peptide derived from the cathelicidin protein [3] . Since LL-37 is the only human antimicrobial peptide in the cathelicidin family and shows a broad spectrum of antimicrobial activity [4, 5] , there is a significant interest in developing this peptide for pharmaceutical applications. It is initially expressed as a 18 kDa human cathelin-associated protein (hCAP18), and the 14-kDa N-terminal cathelin-like domain that binds and sequesters the peptide [6] must be removed in order for LL-37 to become active. In addition to its antimicrobial activity, it has been reported to be chemotactic for monocytes, T lymphocytes, neutrophils, and mast cells [7, 8] , and capable of modulating the expression profile of chemokines, chemokine receptors, and additional genes in macrophages and other mammalian cells [9] . More recently, LL-37 has been found to have additional defensive roles: binding and neutralizing LPS [10] [11] [12] [13] [14] , promoting re-epithelialization and wound closure [15] , regulating the inflammatory response [16] [17] [18] and chemoattracting cells of the adaptive immune system to wound or infection sites at concentrations below the levels required for antimicrobial activity [7, 19, 20] .
Recent studies have shown that LL-37 functions via the bacterial membrane-disruption by interacting with phospholipids of the membrane [21, 22] . However, understanding the detailed mechanism of lipid bilayer disruption, oligomeric nature of LL-37 in a membrane environment, and the threedimensional structure of the peptide will be highly valuable. Since the peptide is structured and oligomerized in solution as well as in membranes, structure of the peptide determined using solution and solid-state NMR experiments would be effective tools for deciphering such a mechanism to a high degree of resolution. However, large quantities (tens of milligrams) of pure recombinant peptide labeled with isotopes are required for such studies. In order to provide large quantities of these peptides for physiological and structural investigations, suitable production methods are necessary. Antimicrobial peptides with a short length of amino acid sequence can be prepared by a solid phase chemical synthesis, but could be very expensive particularly for obtaining a large quantity of labeled peptide. On the other hand, recombinant methods permit the production of peptides and proteins in microorganisms. We report for the first time a method to express and purify LL-37 using Glutathione S-transferase (GST) fusion system. In this study, the E. coli strain, BL21 (DE3), and GST fusion partner were used to produce the recombinant LL-37, both unlabeled and labeled with 15 N. An E. coli expression system was constructed for production of the peptide and a large-scale purification was developed. In this study, we show that the expression of LL-37 can be facilitated by the hCAP18 and considerable amounts of LL-37 can be obtained by this efficient purification method.
Materials and methods

Materials
The cDNA of LL-37 and expression vector pGEX-4T3 were generously provided by Dr. Ole Sorensen, Lund University, Lund, Sweden. Host cell E. coli BL21(DE3) strain and Factor Xa were purchased from Novagen (Madison, Wisconsin). Restriction endonucleases, BamHI and EcoRI, were from GibcoBRL Life Technologies. T4 DNA ligase was also from Promega. Plasmid extraction kit was from Qiagen. Acrylamide, bisacrylamide, SDS, and Tricine were from Bio-Rad. GSTrap FF column and thrombin were from Amersham Biosciences Corp. 15NH4Cl was purchased from Cambridge Isotope Laboratories. Rabbit IgG anti-LL-37 antibody was generously provided by Dr. Birgitta Agerberth, Karolinska Institute, Stockholm, Sweden.
Construction of the pGEX-LL-37 expression vector
The expression vector pGEX-4T3-LL37 was constructed in the laboratory of Dr. Ole E. Sorensen. A Factor Xa cleavage site was inserted to the N-terminal of the cDNA of LL-37. It encodes 26-kDa glutathione S-transferase of Schistosoma japonicum and the amino acids of LL-37, connected by site-specific recognition sequences for both thrombin and Factor Xa. The expression vector pGEX-4T3-LL-37 was transformed to E. coli JM109 competent cells and screened in LB medium containing ampicillin (100 μg/ml). The expression vector was confirmed on an agarose gel after double digestions with BamHI and EcoRI and further confirmed by DNA sequencing using the primer with a sequence: GGG CTG GCA AGC CAC GTT TGG TG. Finally, the successfully constructed expression vector pGEX-4T3-LL37 was then used to transform to E. coli strain BL21(DE3) competent cells (Novagen) for expression purpose and transformants were selected by growth on Luria-Bertani (LB)/ampicillin plates. The positive clone harboring the recombinant plasmid was designed as BL21-GST-LL-37.
Expression of GST-LL-37 fusion protein
A 100 ml culture on a standard M9 minimal growth media supplemented with 100 μg/ml ampicillin was started by inoculating single E. coli BL21-GST-LL-37 colony, and agitated for ∼16 h at 250 rpm at 30°C to OD 600 nm of ∼1.0. For GST-LL-37 expression, the bacteria were diluted (1:10) into standard M9 minimal medium and grown at 30°C until OD 600 nm ∼0.7. Protein expression was induced with 0.1 mM IPTG and cells were harvested after 6 h of incubation at 30°C. All cells were harvested by centrifugation at 5000×g for 30 min at 4°C. Pellet was washed in 1/20 culture volume of PBS.
The production of the 15 N-labeled LL-37 peptide was carried out by culturing E. coli BL21 (DE3) harboring recombinant expression vector pGEX-4T3-LL37 in a M9 minimal medium with 15 N-labeled ammonium chloride as the sole nitrogen source. The general protocol for 15 N labeling is as follows. Cells were overnight cultured in 50 ml of M9 minimal growth medium supplemented with 100 μg/ml ampicillin at 30°C by shaking at 250 rpm. The overnight cultured cells were pelleted by a 30-min centrifugation at 5,000×g. The cells were then washed and pelleted using an M9 minimal growth medium, excluding all nitrogen sources. The pelleted cells were resuspended in 5 ml of M9 minimal medium, which includes 15 NH 4 Cl as sole nitrogen source ( Table 1 ). The resuspended cells were inoculated to 1 l of M9 minimal medium containing 15 NH 4 Cl, then incubated to allow the recovery of growth and clearance of unlabeled metabolites. Upon reaching optical cell densities at OD 600 nm ∼0.7, protein expression was induced by adding 1 ml of 1M IPTG and 2.5 ml of 20% (w/v) D-glucose. After a 7-h incubation period the cells were harvested by centrifugation at 5000×g for 30 min at 4°C. Pellet was washed in 1/20 culture volume of PBS.
Purification of GST-LL-37 fusion protein
The pellet (10 g wet) washed with PBS was resuspended in 100 ml 1× PBS buffer (pH 7.4) and 5 mM DTT. After addition of a 10 mg lysozyme (Sigma) per 1 g of bacteria, the resuspension was sonicated three times for 15 s at 18 μm probe using a Sonifier 250 (Branson, output = 20) on ice. The suspension was stirred at room temperature for 2 h followed by the addition of Triton X-100 to a Table 1 Components of 1L of supplemented minimal medium for the production of 15 4 5.0 ml (3) 1g 15 NH 4 Cl/10 ml sterile dH 2 O (sterile filtered) (4) 10 ml of 20% (w/v) D-glucose (sterile filtered) (5) 2 ml of 1.0 M MgSO 4 (autoclaved) (6) 1 ml of ampicilin (100 mg/ml) final concentration of 1% and incubated by stirring at 4°C overnight. The suspension was ultra-centrifuged at 105,000×g for 1 h to remove cell debris and other particles. The GST-LL-37 fusion protein from the clear supernatant was affinity purified using a 1-ml GSTrap FF column, equilibrated in 20 ml ice-cold binding buffer (1× PBS, pH 7.3) containing 5 mM DTT. The clear supernatant was loaded to the GSTrap FF column at a flow rate of 0.5 ml/min. The column was washed with 10 column volumes of 1× PBS, pH 7.4, containing 5 mM DTT at a flow rate of 1 ml/min to remove unbound proteins. GST-LL-37 was eluted from the column at 4°C with 5 volume of elution buffer (50 mM Tris-HCl, pH 8.0, containing 10 mM reduced glutathione and 5 mM DTT). The flow-through was collected in 0.5 ml fractions and reserved until the procedure has been successfully completed. The presence and purity of eluted GST-LL-37 was evaluated by SDS-PAGE using 12% SDS gels.
Dialysis and Factor Xa cleavage of GST-LL-37 fusion protein
The solution containing GST-LL-37 protein was dialyzed against 400 volumes of Factor Xa cleavage buffer (50 mM Tris-HCl, 150 mM NaCl, and 1 mM CaCl 2 , pH 7.5) for overnight. For cleavage of LL-37 from GST tag, the dialyzed GST-LL37 fusion protein solution was incubated with Factor Xa cleavage buffer plus 80 U Factor Xa for 16-24 h at 21-23°C. The cleavage reaction was stopped by freezing the sample at −20°C. The cleaved protein solution was applied to a reverse-phase HPLC chromatography to purify LL-37.
LL-37 purification
The GST-LL-37 protein solution digested by Factor Xa was redissolved in 0.1% (v/v) trifluoroacetic acid/water (2 ml) and injected onto a (10 × 250 mm) Vydac C 18 reverse-phase HPLC column (Separations Group) equilibrated with 25% acetonitrile containing 0.1% (v/v) trifluoroacetic acid/water at a flow rate of 1.0 ml min −1 . The concentration of acetonitrile in the eluting solvent was raised from 25 to 70% (v/v) with a linear gradient for 60 min. Absorbance was monitored at 214 nm and fractions (1 min) were collected. The concentration of LL-37 was determined by comparing its peak area with that of the chemically synthesized LL-37. The eluted LL-37 was freeze-dried with a BenchTop Freeze Dryer (VirTis, USA) and re-dissolved in sterile PBS. The molecular weight and homogeneity of the LL-37 was analyzed by MALDI-Tofspec-2E instrument (Micromass®, UK) and by SDS-PAGE.
Quantification and identification of LL-37
Quantification of the recombinant GST-LL-37 was performed by Bradford assay. Purity of GST-LL-37 protein preparations was analyzed by SDS-PAGE using 12% SDS gels. The purified LL-37 was analyzed by SDS-PAGE using a 15% Tris-Tricine running gel. SDS-PAGE [23] was performed with Bio-Rad systems according to the instruction given by the manufacturer (Bio-Rad, Hercules, CA). The gels were visualized by staining with Coomassie brilliant blue R250 or by silver staining. For Western blot analysis, proteins on SDS-PAGE were transferred electrophoretically onto nitrocellulose membrane for 2 h at 100 V. The membrane was first blocked with 5% (w/v) nonfat dry milk in TBST (150 mM NaCl, 25 mM Tris, and 0.1% Tween 20, pH 7.5) overnight at 4°C
. Then, the membrane was incubated with diluted rabbit polyclonal LL-37 antibody (1:1000) in 5% nonfat milk TBST for 2 h at room temperature, followed by incubation with horseradish peroxidase-conjugated anti-rabbit IgG from monkey (Amersham Biosciences) (1:2000 diluted in 5% nonfat milk TBST) for another 2 h at room temperature. Detection was performed by enhanced chemiluminescence (Amersham Biosciences) as described by the supplier and the light produced was exposed to Hyperfilm ECL (Amersham Biosciences).
GST activity assay
The presence of the GST-LL-37 fusion protein was monitored by evaluating the GST activity in the bacterial extracts using GST-Tag Assay kit (Novagen). For the detection of enzymatic activity, 1-chloro-2,4-dinitrobenzene (CDNB) was used as substrate. The GST-mediated reaction of CDNB with glutathione produces a conjugate that can be monitored by measuring absorbance at 340 nm.
Briefly, 880 μl of deionized H 2 O, 100 μl 1 M potassium phosphate, pH 6.5, and 10 μl 20 mM CDNB in ethanol were mixed and added with 50 μl of 100 mM reduced glutathione. Absorbance change at 340 nm was measured for 5 min in a spectrophotometer (Cary 300 Bio) at room temperature. The mass of GST-LL-37 was calculated from the standard curve.
MALDI-TOF-MS analysis
The molecular weight and homogeneity of LL-37 were analyzed by a matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometer (Micromass®, UK). Mass spectrometric analysis was performed on a MALDI-Tofspec-2E instrument (Micromass®, UK) equipped with a pulsed nitrogen laser emitting at 337 nm. Pressure in the ion chamber was maintained between 1 × 10 −7 and 4 × 10 −7 Torr. The matrix solution contained 10 mg/ml sinapinic acid dissolved in 50/50 acetonitrile/water with 0.1% TFA. A 10 μl of matrix solution was added to the LL-37 vial, spotted on the target, and evaporated to dryness. The instrument was externally calibrated with a mixture of α-chain ([M + H] + = 3497.0 Da) and β-chain of insulin (M + H]+ = 5731.6 Da) in the sinapinic acid matrix. The instrument was operated in reflection mode with delayed extraction and the accelerating voltage in the ion source was 25 kV. The accuracy of mass determinations was within 0.02%.
Results
Construction of an expression vector
In this study, we confirmed an expression vector, pGEX-4T3-LL-37, which would overproduce a protein containing LL-37, fused to the carboxy-terminus of glutathione S-transferase in E. coli (Fig. 1 ). This vector was designed to express human LL- Fig. 1 . Map of the recombinant expression vector pGEX-4T3-LL-37. cDNA of the human LL-37 (37-amino acids) and Factor Xa cleavage sequence (IEGR) was inserted into the BamHI and EcoRI sites of pGEX-4T3 downstream from the GST gene. Expression of the GST-LL-37 fusion protein is controlled by the tac promoter (Ptac). The vector also contains the ampicillin resistance gene (Amp r ), the pBR322 origin of replication (pBR322 ori), and the lac I q gene. T and F denote thrombin and Factor Xa cleavage sites, respectively. 37 gene fused to GST gene. The LL-37 gene was placed downstream GST encoding DNA in the same open reading frame by inserting the gene into the BamHI and EcoRI restriction sites in the multiple cloning sites of pGEX-4T3. Between GST and LL-37 there were site-specific recognition sequences, both thrombin and Factor Xa, for the release of intact LL-37 (Fig. 1) . The recombinant plasmid with correct reading frame was confirmed by DNA sequencing. Expression of the fusion protein is controlled by the tac promoter.
Induction of fusion protein expression
The constructed vector was expected to encode a fusion protein of 287 residues with the expected molecular weight of 33,370 Da. To determine whether pGEX-4T3-LL-37 could generate the expression of the fusion protein, E. coli BL21 cells harboring the plasmid were treated with 0.1 mM IPTG. The expression of a~33 kDa protein was induced in the presence of IPTG (Fig. 2, lane 2) . The relative migration of the new protein corresponds to that predicted for a fusion between LL-37 (MW of 4.5 kDa) and GST (MW of ∼29 kDa). The amount of the expressed fusion protein was estimated to be 15-30% of the total protein in E. coli BL21 harboring pGEX-4T3-LL-37 plasmid as judged from Coomassie Blue staining (Fig. 2) . These results show that E. coli BL21 harboring pGEX-4T3-LL-37 plasmid expresses recombinant GST-LL-37 fusion protein as expected.
Purification of GST-LL-37
Both the unlabeled and 15 N-labeled GST-LL-37 fusion proteins were purified from the supernatants of cell lysates using a 1 ml GSTrap FF (Amersham Biosciences) column equilibrated with binding buffer. Elution with reduced glutathione buffer yielded over 8 mg/l of culture of GST-LL-37 at >95% purity (Fig. 2 , lane 5 and Table 2 ). Intense bands corresponding to the molecular weights of the expected proteins were shown: 29 kDa for GST and 33 kDa for GST-LL-37. The presence of a band at 29 kDa size may be caused by intracellular cleavage of the fusion protein, or by translational pausing at the junction between GST and the fusion partner. Excessive sonication in the step of cell lysate preparation may also lead to denaturation and breakdown of the fusion protein, which results in the appearance of a band at 29 kDa size. The recombinant GST-LL-37 fusion protein expressed in this condition was from soluble fractions, not from inclusion bodies. The recombinant protein was further confirmed by Western blot using LL-37 antisera raised from rabbit as shown in Fig. 3 . The result showed a strong band at a molecular weight of 33 kDa, confirming that E. coli BL21 strain harboring pGEX-4T3-LL-37 vector expressed recombinant GST-LL-37 fusion protein as expected.
Production of recombinant LL-37
The GST-LL-37 fusion protein sequentially consisted of the following regions from its N-terminus: the GST domain Fig. 2 . SDS-PAGE of a recombinant GST-LL-37 fusion protein purified at different stages of the procedure given in Table 1 . GST-LL-37 was purified from E. coli BL21 using a glutathione affinity chromatography. Lane 2 is the extract of IPTG-induced E. coli BL21 (DE3) containing the expression vector pGEX-4T3. Lanes 3 and 4 are the solubilized supernatant of IPTG-induced E. coli BL21 (DE3) with Triton X-100 and the supernatant ultra-centrifuged at 10,5000×g, respectively. Lanes 5 and 6 are the recombinant GST-LL-37 purified using GSTrap FF column chromatography and synthetic LL-37, respectively. Both lanes 1 and 7 are protein molecular weight markers (kDa). The wet weight of cells after IPTG induction for 6 h at 30°C was ≈ 4 g per liter culture. GST-LL-37 content was estimated by GST activity assay. a The amount of LL-37 was calculated from the mass ratio compared to the determined amount of fusion protein.
b Not determined. (consisted of 240 residues), thrombin and BamHI recognition sites (6 residues), Factor Xa cleavage site (4 residues), and the LL-37 domain (37 residues). Thus, the fusion protein was expressed with 287 amino acid residues which correspond to the molecular weight of 33,370 Da as expected. The recombinant LL-37 peptide can be harvested from the fusion proteins by the cleavage with either Factor Xa or thrombin. Western blot analysis, after SDS-PAGE using a 15% Tris-Tricine running gel and its transfer to nitrocellulose membrane, confirmed the presence of recombinant LL-37 with different molecular size from the two-enzymatic digestions as expected (Fig. 3, lanes 5  and 6) . The recombinant LL-37 peptide was first cleaved from their GST fusion proteins by enzymatic digestion with various concentrations of Factor Xa. The efficiency of this reaction was 50% cleavage using 10 U of Factor Xa/mg of the fusion protein at 22°C for 16-24 h (data not shown). The result showed that one single band corresponding to approximately 4.5 kDa, the same size as the chemically synthesized LL-37, was observed under the Western blot analysis (Fig. 3, lane 5) . As pGEX-4T3 vector contains one thrombin site, the recombinant LL-37 peptide was also obtained from the GST-LL-37 fusion protein by enzymatic digestion with thrombin (Fig. 3, lane 6) . Thus, the recombinant LL-37 peptide obtained by enzymatic digestion with thrombin showed a longer size than that of chemically synthesized LL-37 as expected. Production of the longer size of recombinant peptide by the digestion with thrombin was from the presence of the 6 extra amino acid residues, Gly-Ile-Ile-Glu-Gly-Arg, at the N-terminus of LL-37. Western blot analysis, after SDS-PAGE using a 15% Tris-Tricine running gel and its transfer to nitrocellulose membrane, confirmed the presence of recombinant LL-37 with different molecular size from the two-enzymatic digestions as expected (Fig. 3 , lanes 5 and 6).
Purification of recombinant LL-37
The recombinant LL-37 peptide from the cleavage products with Factor Xa was purified by applying the cleavage product to reverse-phase HPLC on a Vydac C18 column (Fig. 4A ). All the eluted fractions were analyzed on a 15% Tris-Tricine SDS-PAGE gel (Fig. 4B) . The fraction eluted at 43 min of retention time contained a single band with an apparent molecular weight of 4.5 kDa, suggesting as LL-37. The fraction eluted at 41 min of retention time contained both LL-37 and GST-LL-37. The fractions at peaks 1-4 were identified as GST-tag, GST-LL-37, a mixture of GST-LL-37 and LL-37, and LL-37, respectively. The identity of LL-37 was confirmed by MOLDI-TOF mass spectrometry (Fig. 5 ). On MALDI-TOF MS, singly protonated molecular ion (M + H)+ of the purified LL-37 was observed at m/z 4492.4 Da while the calculated molecular mass is 4493.3 Da. The eluted LL-37 was freezedried with a bench top freeze dryer (VirTis, USA) and dissolved in sterile PBS. The final yield of purified LL-37 per liter of culture was ∼0.3 mg/l ( Table 2 ). The total recovery of the peptide was 7%. The apparent decrease in protein yield after affinity chromatography using GSTrap FF column was due to removal of the fusion partner. The decrease was also partly due to incomplete digestion of the GST-LL-37 fusion protein by Factor Xa.
Discussion
Recently, antimicrobial peptides have been studied extensively because of their possible clinical applications as agents for the treatment of infective diseases. Among these antimicrobial peptides, LL-37 is a very promising candidate because it originates from human. The highly efficient production of biologically active LL-37, with large quantity and low cost, is an absolute need for both structure-function relationship investigation and potential clinical applications. In particular, characterization of the molecular mechanism of lipid bilayer disruption by LL-37 is our final goal by employing solution and solid-state NMR spectroscopy. Due to the need for large quantity of LL-37 for these studies, we sought a production method of LL-37 utilizing E. coli, as it yields a high level of pure and uniformly labeled protein necessary for experimental studies. In the current work, we constructed a highly efficient system for the expression and purification of a human LL-37 in E. coli, using the pGEX-4T3 expression vector with a tac promoter. There are no methods reported for the direct expression of recombinant LL-37 so far. While our research was on progress, Yang et al. [24] had reported the expression of a variant of LL-37 that has two extra amino acid residues, Gly-Ser, in its Nterminus. Since the activity of a peptide is sensitive to the exact amino acid sequence, the presence of unnecessary Gly and Ser residues could lead to biological activities that may differ from that of LL-37. In our study, a fusion protein between GST and LL-37 was produced from an E. coli strain harboring a recombinant pGEX-4T3-LL-37 plasmid. The bacterial strain was grown on M9-Amp minimal medium (glucose, MgSO 4 , CaCl 2 , ampicillin) including 15 NH 4 Cl, since this media contains only one source carbon and nitrogen and will be used for uniform labeling of isotope. Over expression of the GST-LL-37 construct did not limit the cell growth (OD 595 nm of induced cultures 1.0-1.3, uninduced was 1.3), indicating that GST is able to sequester LL-37 and prevent it from killing the E. coli host. The fusion protein was expressed into the cytoplasm where it could be recovered following lysis of the bacteria.
Normally, recombinant fusion proteins should be cleaved to release the peptide of interest for clinical and biological studies. Factor Xa protease is one among of few proteases that permits the release of the target protein without additional N-terminal residues. In this study, we constructed the GST-LL-37 by inserting Factor Xa cleavage site to cleave the LL-37 peptide from the GST tag cleanly with no extra residues left attached to the peptide. A Factor Xa recognition site between BamHI restriction enzyme site and oligonucleotides encoding the 37 amino acid residues of LL-37 was inserted to correctly cleave LL-37 peptide from GST-LL-37 fusion protein. The GST is a soluble cytoplasmic protein, which is well established as a useful partner for highly soluble and stable fusion proteins, used in the expression of many biologically active mammalian growth factors and cytokines in E. coli. This method of releasing LL-37 using Factor Xa together with the high-level expression as a GST fusion protein readily constitutes a good system for rapid production of LL-37. In our study, recombinant LL-37 was directly and easily purified using the reverse-phase HPLC after the enzymatic digests of GST-LL-37 fusion protein with Factor Xa.
In our study, a relatively high amount of the recombinant GST-LL-37 fusion protein was in soluble form, while some amount of the fusion protein was also found in inclusion body. The final yield of purified LL-37, 0.3 mg per liter of culture, could be improved by increasing the solubility of GST-LL-37. The expression and yield of the fusion protein were influenced by the temperature of the culture during induction and by the concentration of IPTG. In our preliminary study, we found that culture of BL21(DE3) in the presence of 1.5 mM IPTG at 37°C resulted in the degradation of the GST-LL-37 fusion protein or the formation of inclusion body, which was difficult to recover (data not shown). We found that induction of the recombinant GST-LL-37 fusion proteins, both unlabeled and labeled with 15 N, at low temperature (30°C) and low IPTG (0.1 mM) concentration greatly improved the yield of intact soluble GST-LL-37 fusion protein for all densities and induction times tested (data not shown). Co-expression with molecular chaperones, TF and GroEL-GroES [25] [26] [27] , may play cooperative roles in improving the solubility of GST-LL-37. The yield of the fusion protein was also influenced by the presence of nonionic detergent, Triton X-100, in cell lysate buffers. 1% Triton X-100 in the extraction buffer greatly improved the recovery of GST-LL-37 from E. coli (data not shown). It may be possible to improve the yield using other recombinant procedures for producing short cationic antimicrobial peptides in bacteria [28] .
In summary, we constructed an efficient system for the expression and purification of a LL-37 in E. coli, using the pGEX-4T3 expression vector with a tac promoter. To the best of our knowledge, it is the first report on the effective expression and purification of intact and bioactive human LL-37. It was confirmed that the fusion expression system produced soluble GST-LL-37 (LL-37 fused with GST) and that the recombinant LL-37 peptide could be obtained from the fusion protein through the enzymatic digestion with Factor Xa or thrombin. The expression system and purification method of LL-37 will be fully helpful in the structural and functional studies of LL-37. In the near future, the availability of purified LL-37 could also enable the clinical, structural, biochemical, and biological investigations.
Amino acid selective and uniform labeling of LL-37 with 15 N, 13 C, 19 F and/or 2 H would enable a plethora of biophysical studies (as reported in the literature [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] ) to understand the membrane-peptide interactions, peptide-induced changes in the membrane, and the role of membrane composition. Studies to determine the structural folding, oligomerization and dynamics of LL-37 and its analogs in water versus membrane are in progress in our laboratory using a variety of solid-state NMR experiments.
